Tonix Pharmaceuticals Holding Overview

Tonix Pharmaceuticals Holding Selling, General & Admin

Selling, General & Admin expenses for TNXP.

Quarterly SG&A Expenses

$28.07M

↑ 177.8% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$79.95M

↑ 101.43% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin